Benzinga | Aug 16, 2021 08:42AM EDT

Canaccord Genuity Maintains Buy on CRISPR Therapeutics, Raises Price Target to $160

Canaccord Genuity analyst Arlinda Lee maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $151 to $160.